Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq,...
Corcept Therapeutics faces a securities fraud class action after alleged FDA approval issues and an approximately 50% stock decline, with law firm Kahn Swick & Foti soliciting potentially affected investors to contact counsel.
Why it mattersFDA approval uncertainty for Corcept and 50% stock decline requires investors to reassess biotech portfolio exposures.